Rheumatoid arthritis (RA) is an autoimmune disease in which the body’s own immune system attacks its joint tissues, which leads to inflammation of joint lining. Such inflammation of joint lining causes pain, stiffness, swelling, warmth, and redness.The global rheumatoid arthritis diagnostic tests market is estimated to account for US$ 3,480.9 Mn in terms of value by the end of 2027
Increasing prevalence of RA is expected to propel growth of the global rheumatoid arthritis diagnostic tests market over the forecast period. For instance, according to the study, “Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017”, published in the journal Annals of the Rheumatic Diseases, in November 2019, the age-standardized point prevalence and annual incidence rates of RA were 246.6 and 14.9 in 2017, which increased by 7.4% and 8.2% from 1990, respectively.
We do offer sample of this report. Kindly go through the follow information in order to access sample copy:- https://www.coherentmarketinsights.com/insight/request-sample/3716
Moreover, increasing expenditure for the treatment and management of RA is also expected to aid in growth of the market. For instance, according to the study, “Mortality, disability, and healthcare expenditure of patients with seropositive rheumatoid arthritis in Korea: A nationwide population-based study”, published in the journal PLOS One in January 2019, the annual health expenditures were significantly larger for patients with RA than for controls.
Asia Pacific held dominant position in the global rheumatoid arthritis diagnostic tests market in 2019, accounting for 41.1% share in terms of value, followed by Europe, respectively
Global Rheumatoid Arthritis Diagnostic Tests Market: Restraints
Limited specificity and sensitivity of test kits available in the market is expected to hinder growth of the global rheumatoid arthritis diagnostic tests market.
Moreover, lack of effective drugs for the treatment of RA is also expected to limit growth of the market.
Introduction of cost effective and reliable test kits is expected to offer lucrative growth opportunities for players in the market. Presently, there are no effective diagnosis measures available for rheumatoid arthritis. The unavailability of effective diagnostic tools has triggered the need for cost effective and more reliable test kits. As a result, the companies operating in this market are now focusing on the development of cost-effective and reliable test methods.
Moreover, R&D of biomarker-based diagnostic methods for RA is also expected to aid in growth of the market. For instance, in February 2020, researchers from Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Germany, reported that serum markers can be used to detect inflammation in patients in joint diseases The hospitals segment of global rheumatoid arthritis diagnostic tests market was valued at US$ 614.1 Mn in 2019 and is forecast to reach a value of US$ 1,062.8 Mn by 2027 at a CAGR of 7.1% between 2019 and 2027
In the recent past, the techniques for diagnosing RA have made significant progress in terms of rapid outcomes. The serology test is now being performed on the rapid diagnosis test platform, which helps in conducting RA test within the stipulated time. A large number of pathology centers are increasingly relying on such rapid diagnostic tools, owing to increasing in-patient visit for RA testing.
Application of biomarker test for diagnosing RA is at an early stage of development. Many companies are focusing on the development of biomarker test, owing to the limited efficacy of test kits available in the current market. Presently, there is no biochemical test available for the diagnosis of RA. However, Rheumatoid Factor (RF) and Anti–Cyclic Citrullinated Peptide (anti–CCP) antibodies test require more refinement to improve their clinical utility.
Major players operating in the global rheumatoid arthritis diagnostic tests market include, Abbott Diagnostics (Abbott Laboratories), Antibodies Inc., Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.
Major players in the market are focused on adopting partnership strategies to expand their product portfolio. For instance, in March 2020, WorldCare Clinical, LLC, an independent CRO offering imaging in clinical trials partnered with Navidea Biopharmaceuticals, Inc. to offer imaging service following FDA approval of Navidea’s RA diagnostic.
Get the main link:- https://www.coherentmarketinsights.com/market-insight/rheumatoid-arthritis-diagnostic-tests-market-3716
ContactUs:
Mr.Shah
Coherent Market ,Insights
10014thAve,
#3200
Seattle,WA98154
Tel:+1-206-701-6702
Email: [email protected]